Profile of sarilumab and its potential in the treatment of rheumatoid arthritis.

摘要: In recent years the use of biotechnological agents has drastically revolutionized therapeutic approach and progression rheumatoid arthritis (RA). particular, interleukin-6 (IL-6) been demonstrated as a pivotal cytokine in pathogenesis disease by contributing to both innate adaptive immune system perturbation, production acute-phase proteins involved systemic expression disorder. The first marketed IL-6 blocker was tocilizumab, humanized anti-IL-6 receptor (anti-IL-6R) monoclonal antibody. successful tocilizumab RA encouraged development other biologic specifically targeting pathway, either directed against (sirukumab, olokizumab, clazakizumab) or (sarilumab). One Phase II six III randomized controlled trials broad efficacy sarilumab across all patient subtypes, ranging from methotrexate (MTX) tumor necrosis factor inhibitor insufficient responders. monotherapy clear head-to-head superiority over adalimumab MTX-intolerant subjects. addition, compared with showed similar safety profile significantly higher affinity longer half-life, responsible for reduction frequency administration (every week instead weekly). All these aspects may be important defining strategy positioning treatment algorithm RA. Indeed, observational data coming post-marketing real-life studies provide crucial additional information better understanding role management disease. This review summarizes biological clinical available on an alternative option patients.